65 studies found for:    GIST | Open Studies
Show Display Options
Rank Status Study
1 Unknown  Radiation Therapy as Palliative Treatment of GIST
Condition: Sarcoma
Intervention: Radiation: Radiation therapy (external beam photons)
2 Recruiting A Study of Nilotinib Versus Imatinib in GIST Patients
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107);   Drug: imatinib (STI571)
3 Recruiting Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Condition: Gastrointestinal Stromal Tumors
Intervention: Other: Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
4 Recruiting MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: MEK162;   Drug: Imatinib Mesylate (Gleevec®; STI571; NSC #716051)
5 Recruiting A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: AUY922
6 Recruiting Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy
Condition: Gastrointestinal Stromal Tumor
Intervention:
7 Unknown  Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
Conditions: Renal Cell Cancer;   Colorectal Cancer;   GIST
Intervention: Other: Questionnaires
8 Recruiting A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
Condition: 3rd Line GIST
Intervention: Drug: ST571 + BYL719
9 Recruiting A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients
Condition: 3rd Line GIST
Intervention: Drug: STI571 + BKM120
10 Recruiting Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
Condition: GIST
Intervention: Drug: Vandetanib
11 Recruiting Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: Sunitinib;   Drug: Regorafenib
12 Not yet recruiting Ph II CABOGIST in GIST
Condition: Metastatic Gastrointestinal Stromal Tumor
Intervention: Drug: cabozantinib
13 Recruiting A Retrospective Study of C-kit Mutation Status in Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib.
Condition: Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib
Intervention: Procedure: Tumor biopsies
14 Recruiting A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Condition: GIST
Intervention: Drug: ponatinib
15 Recruiting Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
Condition: Gastric Cancers
Intervention:
16 Recruiting A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: sunitinib malate dose escalation;   Drug: sunitinib malate
17 Available Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (BAY73-4506)
18 Not yet recruiting Masitinib vs Placebo - Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
Condition: Gastro-Intestinal Stromal Tumour
Interventions: Drug: Masitinib;   Drug: Placebo
19 Recruiting Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Condition: Advanced Gastrointestinal Stromal Tumors
Intervention: Drug: PD-0332991 will be administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.
20 Recruiting Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: AUY922

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years